On May 6, Dr. Kenneth Tsang, Regional Chief Executive Officer, IHH Healthcare North Asia and Chief Executive Officer, Gleneagles Hospital Hong Kong, led a delegation to pay an official visit to Guangzhou Royal Lee Cancer Hospital for in-depth inspection and exchanges.The two parties held high-level discussions on international medical tourism, joint academic research, exchange of cutting-edge technologies, cross-border referral, and other key topics, exploring new paths for integrated international medical and wellness development.

Strategic China-Singapore Location Empowers Royal Lee as a Premier International Medical Institution in the Greater Bay Area

Guangzhou Royal Lee Cancer Hospital ,a JCIaccredited international hospital,is located in the China-Singapore Guangzhou Knowledge City — a national-level strategic demonstration zone for bilateral cooperation between China and Singapore. It is a benchmark international medical institution in the region and has been officially designated by Huangpu District as the International Medical and Wellness Base of the China-Singapore Guangzhou Knowledge City.

IHH Healthcare is a listed healthcare group that ranks among the top in Asia and globally, with operations spanning more than ten countries. It owns renowned high-end healthcare brands such as Parkway and Gleneagles. Hong Kong Gleneagles Hospital and Shanghai Parkway Hospital are among its core affiliated institutions. IHH has developed mature systems and a global network in international medical services, oncology diagnosis and treatment, and hospital operations management.

This visit represents a key follow-up and deep connection in the strategic cooperation between the two parties. In April this year, Mr. Li Min, Chairman of Royal Lee Group, and Vice President Ma Lanying led a core team to IHH Healthcare's headquarters for inspection and discussion. This return visit by IHH North Asia’s executive delegation marks a new phase in which both sides move from intention-based exchanges to substantive implementation and comprehensive strategic cooperation.

High-Level Mutual Engagement with Core Management Teams in Attendance

The visiting delegation comprised the core decision-makers of IHH North Asia, led by CEO Dr. Kenneth Tsang. As the head of IHH Healthcare’s North Asia region, Dr. Kenneth Tsang oversees the group’s strategic layout, operational management, and clinical quality enhancement across key North Asian markets, leading its general hospitals, specialty clinics, and ambulatory care centers toward standardized and high-quality international development, and continuously promoting IHH’s long-term, sustainable growth across the entire healthcare industry chain in China.

Dr Kenneth Tsang

Chief Commercial Officer, Ms Joyce

Director of Strategy, Data and Operational Improvement, Mr. Li Bo

Chief of Pharmacy Services and Research, Ms Carol CHOW

Mr. Chen Guo

The hospital’s core management team, including Supervisor Luo Aiming, Deputy General Manager Li Li, Chief Advisor for International Medicine Li Dinggang, Vice President Ma Lanying, Assistant President Tang Haibo,and Director of the Hospital General Office Zhong Yanxia, warmly received the delegation and accompanied them throughout the site visit and special symposium.

Supervisor Luo Aiming

Deputy General Manager Li Li

Chief Advisor for International Medicine Li Dinggang

Vice President Ma Lanying

Site Visit Demonstrates High Quality; International Standards Highly Recognized by Global Healthcare Leader

The delegation visited the hospital’s International Medical Center, advanced diagnosis and treatment wards, high-end medical equipment, and international-standard wellness environment. They experienced first-hand the hospital’s full-process clinical service standards, cross-border medical capabilities, and clinical operation norms, and gave high praise and full recognition to the hospital’s international philosophy, hardware configuration, refined service system, and differentiated development positioning.

During the exchange meeting, Vice President Ma Lanying detailed the hospital’s development history, founding mission, and differentiated international medical strategy, showcasing its solid achievements and mature experience in international patient reception, specialized medical technologies, full-process service support, and cross-border medical coordination. She highlighted how the hospital leverages policy support from the China-Singapore cooperation demonstration zone and key backing from Huangpu District, fully utilizing its international service system, leading diagnostic and treatment equipment, proprietary innovative medical programs, and one-stop wellness facilities to build a unique international medical and wellness hub in the Greater Bay Area.

Dr. Kenneth Tsang, CEO of IHH Healthcare North Asia, stated during the meeting that his visit to Guangzhou Royal Lee Cancer Hospital fully demonstrated the hospital’s commitment to a differentiated, high-quality, and international development positioning in terms of hardware facilities, service systems, and medical technology. He noted that the hospital’s direction is highly accurate and its positioning exceptionally clear, aligning closely with global trends in international healthcare.He pointed out that Royal Lee Hospital shares strong synergies with IHH and its Parkway brand in development philosophy, patient-centered service, and international treatment standards. IHH has always been dedicated to advancing differentiated treatment, innovative therapies, and precision medicine. Meanwhile, the China-Singapore Guangzhou Knowledge City is home to a large number of biomedical innovation enterprises, cutting-edge technology platforms, and high-quality medical resources. He emphasized that there is broad potential for cooperation between the two sides in areas such as innovative drug collaboration, cross-border clinical research, international patient services, and multidisciplinary team (MDT) diagnosis and treatment.

Professor Li Dinggang  suggested deepening cooperation to jointly create a pathway for Chinese doctors to go global, systematically export top-tier Chinese medical experts and independent innovative technologies, effectively tell China’s medical story to international markets, address information asymmetry and insufficient awareness of China’s medical capabilities abroad, and jointly promote high-quality Chinese medical resources to the world.

Forging Consensus on Deepened Cooperation

Synergizing Across Multiple Sectors to Anchor a Long-term Development Blueprint

The two parties conducted an in-depth analysis of the differences between the Chinese and international healthcare sectors, the complementarity of resource endowments, and the pain points in cross-border medical development, based on the global healthcare landscape. Guided by the core principles of complementary advantages, resource sharing, mutual benefit and win-win cooperation, and joint expansion into international markets, they reached a number of key consensuses.

The parties will carry out in-depth cooperation in four key areas: international physician development and brand building, global rollout and promotion of China’s innovative medical technologies, development of a differentiated high-end international medical service system, and establishment of a regular exchange and collaboration mechanism. Together, they will explore new paths for the integrated development of cross-border healthcare, advance the implementation of both parties’ internationalization strategies, and achieve complementary advantages and mutual benefits.

Through this symposium, both sides thoroughly clarified the underlying logic of cooperation, defined long-term development pathways, and aligned strategic goals, removing obstacles and laying a solid foundation for comprehensive and deep strategic cooperation. During the meeting, both parties formally confirmed that they will take this high-level engagement as an opportunity to accelerate the refinement and formal signing of a strategic cooperation agreement, promptly clarify implementation responsibilities, coordination processes, and milestones, and take gene therapy and other specialized technologies as benchmark demonstration projects — piloting, rapidly implementing, and creating models, gradually expanding the scope of cooperation from point to area.

In the future, against the backdrop of China-Singapore national-level bilateral cooperation and with the Greater Bay Area’s international medical development as the core platform, both sides will fully leverage their respective core strengths, work together to break down global medical resource barriers, address the shortcomings in China’s medical internationalization, and jointly create a benchmark for China-Singapore medical cooperation, a model for cross-border medical care in the Greater Bay Area, and a demonstration case for Chinese medical innovation going global. With high-quality medical services, they will benefit patients worldwide and jointly expand a new landscape for the global high-end medical and wellness industry.